DP Clinical Continues Growth with Addition of Chief Medical Officer

ROCKVILLE, MD – October 30, 2019 – DP Clinical, Inc., a Contract Research Organization (CRO) specializing in infectious disease, neuroscience, oncology, and ophthalmology Phase I-III clinical programs; recently hired Neil Frazer, MB.Ch.B as its Chief Medical Officer.

Dr. Frazer is located in the Research Triangle Park area of North Carolina and is responsible for providing leadership, strategy, and overseeing the execution of clinical development programs for DP Clinical. With 30 years of experience as a pharmaceutical physician for domestic and global biotechs, pharmaceutical companies, and CROs; Dr. Frazer has provided clinical research, drug development, and product marketing expertise for over thirty drug and device development initiatives in oncology, anti-viral, cardiovascular, dermatology, ophthalmology, respiratory, and gastrointestinal programs in Europe, Australia, and the US.

Dr. Frazer holds an MB.Ch.B (Medical Degree) from the University of Edinburgh Medical School. Dr. Frazer also received the Fellowship of the Royal College of Anaesthetists, London (FRCA) and Fellowship in Pharmaceutical Medicine (FFPM) from the Royal College of Physicians.
“Over the past 25 years, DP Clinical has built an impressive organization with the ability to understand, anticipate, and satisfy our clients’ needs,” said Devinder Poonian, President and CEO. “Part of being a great company is being able to attract the best talent in the industry, and we have done that with the hiring of Dr. Frazer. He is a seasoned professional who will add great value to our growing team,” Ms. Poonian continued. Dr. Frazer commented, “DP Clinical is a focused, dedicated, and specialized CRO with a solid reputation of meeting our partner’s needs in multiple therapeutic areas, and it is a pleasure to help the team meet corporate and client goals.”

2019-10-31T14:29:22+00:00